![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
Coffee Drinkers Get Less Prostate Cancer
Jul. 5th, 2011 04:13 pmhttp://www.medscape.com/viewarticle/745359?src=mp&spon=34
is a review on this study:
Wilson KM, Kasperzyk JL, Rider JR, et al. Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. J Natl Cancer Inst. 2011;103:876-884. Epub 2011 May 17.
but this study
http://cancerres.aacrjournals.org/content/50/21/6836.short
found no correlation at least for survival of fatal prostate cancer, between coffee drinkers or not.
( ...and... coffee drinkers have higher testosterone! text here. video at link above. )
is a review on this study:
Wilson KM, Kasperzyk JL, Rider JR, et al. Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. J Natl Cancer Inst. 2011;103:876-884. Epub 2011 May 17.
but this study
http://cancerres.aacrjournals.org/content/50/21/6836.short
found no correlation at least for survival of fatal prostate cancer, between coffee drinkers or not.
( ...and... coffee drinkers have higher testosterone! text here. video at link above. )
Tags:
http://www.independent.co.uk/life-style/health-and-families/health-news/cancer-shock-breakthrough-1710727.html
Ipilimumab is one of a class of drugs called monoclonal antibodies, which stimulate the body's own immune system to fight disease. The experimental treatment is being developed by Bristol-Myers Squibb and Medarex, a US biotech company. The drug is being trialled on malignant melanoma, the most serious form of skin cancer, Hodgkin's disease, lung cancer and prostate cancer. Studies are most advanced in melanoma, where it has been shown to prolong survival in patients with advanced forms of the disease. In the Mayo Clinic study of prostate cancer, researchers say that standard hormone treatment ignited the immune response, and adding ipilimumab was like "pouring gasoline on the pilot light".
Apparently it caused remarkable recession in several men's prostate cancers. During surgery the pathologists were having a hard time finding any remaining cancer cells.
Ipilimumab is one of a class of drugs called monoclonal antibodies, which stimulate the body's own immune system to fight disease. The experimental treatment is being developed by Bristol-Myers Squibb and Medarex, a US biotech company. The drug is being trialled on malignant melanoma, the most serious form of skin cancer, Hodgkin's disease, lung cancer and prostate cancer. Studies are most advanced in melanoma, where it has been shown to prolong survival in patients with advanced forms of the disease. In the Mayo Clinic study of prostate cancer, researchers say that standard hormone treatment ignited the immune response, and adding ipilimumab was like "pouring gasoline on the pilot light".
Apparently it caused remarkable recession in several men's prostate cancers. During surgery the pathologists were having a hard time finding any remaining cancer cells.
